A biosensor platform that converts plant sugar transporters (SWEETs) into fluorescent sensors to screen chemical libraries for small-molecule inhibitors. Targeting SWEETs could block bacterial blight infection in rice and other crops without genetic modification, offering a novel crop protection strategy.
Bacterial blight, caused by Xanthomonas oryzae pv. oryzae (Xoo), is a major rice disease responsible for substantial yield losses across Asia and Africa. The pathogen exploits sugar transporters of the SWEET family in rice to extract nutrients from host plants, enabling infection. This project proposes a new crop protection approach: instead of genetically modifying plants, small-molecule inhibitors could block SWEET transporter activity and reduce disease susceptibility. The research team is developing a high-throughput biosensor platform to discover such inhibitors from chemical libraries, with potential applications across multiple crops.
Core technology:
Approach and rationale:
Potential applications:
The project is at an early research stage. The proposed biosensor system and high-throughput screening workflow have been conceptualized but not yet validated. Next steps include constructing the SWEET–fluorescent protein fusions, confirming that fluorescence responses correlate with small-molecule binding, and running pilot screens against chemical libraries. Successful validation would advance the platform toward lead compound identification and subsequent agrochemical development.
Georgia Institute of Technology is a large, technology‑focused public research university in Atlanta with a strong applied research culture. Industry engages through the Georgia Tech Research Institute for contract R&D, a Midtown innovation district with co‑located corporate labs, and a statewide manufacturing extension to support scale‑up. A long‑standing partnership with a major academic medical center enables clinical translation, and a large co‑op program delivers a steady talent pipeline. Research is backed by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. Technology commercialization is managed by the Georgia Tech Research Corporation, with dedicated licensing, corporate contracting, and startup support.